棕榈酸帕利哌酮注射液治疗精神分裂症有效性和安全性的Meta分析

发布时间：2018-06-25 08:07

本文选题：棕榈酸帕利哌酮 + 长效针剂　；参考：《中国药学杂志》2014年06期

【摘要】：目的评价棕榈酸帕利哌酮注射液(paliperidone palmitate long-acting injection,PP-LAI)治疗精神分裂症的有效性和安全性。方法系统收集国内外公开发表的棕榈酸帕利哌酮注射液治疗精神分裂症的文献;按照Jadad评分系统对纳入文献进行质量评价;采用RevMan 5.2软件进行数据分析,得到合并的效应值及其95%的可信区间。结果最终纳入12个临床随机对照试验,共39个研究分析集(棕榈酸帕利哌酮注射液组和对照组)。棕榈酸帕利哌酮注射液组的有效率是安慰剂组的1.70倍(95%CI:1.50~1.91,Z=8.55,P0.01),且不劣于利培酮长效针剂组(RR=1,95%CI:0.88~1.13)。同时,棕榈酸帕利哌酮注射液的不良反应事件发生率与安慰剂组(RR=1.01,95%CI:0.97~1.05)和利培酮长效针剂组(RR=1.07,95%CI:0.98-1.16)类似,具有良好的耐受性。结论棕榈酸帕利哌酮在治疗精神分裂症的有效性和安全性方面都具有一定的优势。
[Abstract]:Objective to evaluate the efficacy and safety of (paliperidone palmitate long-acting injection PP-LAI in the treatment of schizophrenia. Methods the literature published at home and abroad on the treatment of schizophrenia with palipiperone palmitate injection was collected systematically, the quality of the literature was evaluated according to Jadad scoring system, and the data was analyzed by RevMan 5.2 software. The combined effect value and its 95% confidence interval are obtained. Results A total of 39 clinical randomized controlled trials were conducted (palmitate injection group and control group). The effective rate of palipiperone palmitate injection group was 1.70 times as high as that of the placebo group (95 CI: 1.50 1.91) and was not inferior to that of risperidone long-acting injection group (RRR195CI0.881.13). At the same time, the incidence of adverse events in palipiperone palmitate injection was similar to that in the placebo group (RRN 1.0195 CI: 0.971.05) and the risperidone long-acting injection group (RRN1.0795CIW 0.98-1.16), and had good tolerance. Conclusion Paripiperone palmitate is effective and safe in the treatment of schizophrenia.
【作者单位】：北京大学中国卫生经济研究中心;四川大学华西公共卫生学院;北京大学国家发展研究院;沈阳药科大学工商管理学院;
【分类号】：R749.3

【共引文献】